Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence? - Abstract

PURPOSE: To evaluate the clinical outcome of a cohort of localized prostate cancer patients treated with 125-I permanent brachytherapy at the São José Hospital - CHLC, Lisbon.

MATERIALS AND METHODS: A retrospective analysis was carried out on 429 patients with low and intermediate-risk of prostate adenocarcinoma, according to the recommendations of the EORTC, who underwent 125I brachytherapies in intraoperative dosimetry "real-time" system between September 2003 and September 2013.

RESULTS: The mean follow-up was 71.98 months. Biochemical relapse of disease by rising PSA (Phoenix criterion) was observed in 18 patients (4.2%). Through the application of Kaplan-Meier survival curves in this sample, the rate of survival at 6 years without biochemical relapse was higher than 95%. By Iog rank test comparing biochemical relapse with initial PSA (15-10 and < 10) and Gleason values (7 and < 7), there was no statistical difference (P=0.830) of the initial PSA in the probability of developing biochemical relapse. In relation to Gleason score, it was noted a statistical difference (P < 0.05), demonstrating that patients with Gleason 7 are more likely to develop biochemical relapse.

CONCLUSIONS: Brachytherapy as monotherapy is at present an effective choice in the treatment of localized prostate adenocarcinoma. Biochemical relapses are minimal. The initial PSA showed no statistically difference in the rate of relapses, unlike the value Gleason, where it was demonstrated that patients with Gleason 7 have a higher probability of biochemical relapse. Cases with PSA bounce should be controlled before starting a salvage treatment.

Written by:
Galego P, Silva FC, Pinheiro LC.   Are you the author?
Section of Urology, São José Hospital, CHLC, Lisboa, Portugal.

 

Reference: Int Braz J Urol. 2015 Mar-Apr;41(2):353-9.
doi: 10.1590/S1677-5538.IBJU.2015.02.24


PubMed Abstract
PMID: 26005979

UroToday.com Prostate Cancer Section